Status:
UNKNOWN
Teriparatide on Maxillary Sinus Floor Osseointegration
Lead Sponsor:
Universidad de Valparaiso
Collaborating Sponsors:
Universidade Federal Fluminense
Conditions:
Bone Regeneration
Eligibility:
All Genders
25-70 years
Phase:
PHASE4
Brief Summary
The aim of this triple blind randomized controlled trial will be to analyze the effect of a dose of teriparatide combined with a xenograft on bone augmentation of the maxillary sinus, to observe the m...
Eligibility Criteria
Inclusion
- Pneumatization of a maxillary sinus with a residual ridge ≤ 5 mm in height (according to baseline conebeam tomograph).
- Must sign an informed consent to participate in this study.
Exclusion
- Residual ridges less than 4 mm in height.
- Uncontrolled systemic disease (ASA 3, 4, 5, and 6)
- Presenting with osteoporosis or any disease of bone metabolism.
- Having received radiotherapy.
- Cancer.
- Any systemic condition that affects calcium absorption.
- Kidney disease.
- Coagulation disorders.
- History of sinusitis.
- Maxillary sinus pathology.
- Heavy smoking (\> 1 pack per day).
- Drug or alcohol users.
- Pregnancy.
- Treatment with drugs that affect bone metabolism.
- Treatment with immunosuppressants.
- Allergies.
- Uncontrolled periodontal pathology.
- Tooth extractions in the last three months.
Key Trial Info
Start Date :
August 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06061354
Start Date
August 23 2023
End Date
December 1 2024
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Facultad de Odontología, Universidad de Valparaiso
Valparaíso, Región de Valparaíso, Chile, 2360004